Astellas/Cardiome Schedule Kynapid Meeting With U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Cardiome's Oct. 9 investor update, announcing a Nov. 14 meeting with U.S. regulators on its/Astellas' Kynapid NDA, adds little clarity on how long the drug's approval process could be delayed